Best Immunotherapy for prostate cancer Doctors Worldwide — TOP 51

Dr. Bulent Karagoz is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in immunotherapy and targeted therapies for sarcoma, lymphoma, and lung cancer. Dr. Karagoz provides treatment at a facility affiliated with the prestigious Johns Hopkins Hospital.

• Authored over 40 research publications focusing on tumor biology and immunology.
• Former Head of Internal Diseases at Istanbul Okan University Faculty of Medicine.
• Held leadership roles in medical oncology at GATA Haydarpasa Training Hospital.
• Member of the Turkish Medical Oncology Association and European Head and Neck Society.

Prof. Merimsky heads the Soft Tissue and Bone Oncology Unit at Sourasky Medical Center – a leader in immunotherapy for prostate cancer.

• Over 41 years of experience specializing in oncology with a focus on immunotherapy
• Fellowship-trained in sarcoma oncology at Institut Gustave Roussy, Paris
• Active member of ESMO Sarcoma group faculty
• Published extensively on tumor immunology and cancer treatment

Dr. Sarid specializes in prostate cancer immunotherapy at Sourasky Medical Center, with extensive training in cancer urology from Oxford University.

• Senior oncologist at Ichilov since 2009
• Principal investigator of clinical trials in cancer therapies
• Published 30+ articles on cancer treatment
• Member of ESMO and ASCO

Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.

Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.

Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.

He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.

He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.

Prof. Sezer Sağlam focuses on medical oncology with extensive experience in immunotherapy for prostate cancer at Gayrettepe Florence Nightingale Hospital.

• Professor in Medical Oncology since 2016
• Fellowship-trained at Istanbul University Medical Faculty
• Member of ESMO, ASCO, and Turkish Medical Oncology Association
• Specializes in gastrointestinal oncology

Dr. Osama Abdel Mohimen Mohamed leads the Hematology Unit at Shefaa Al Orman Oncology Hospital. He treats complex blood cancers, including leukemia, lymphoma, and myeloma. Dr. Mohamed is a member of the European Society for Medical Oncology. He also holds memberships in the American Society of Hematology and ASBMT.

• Specializes in chemotherapy, immunotherapy, and bone marrow transplantation.
• Manages aggressive acute leukemia and chronic blood disorders.
• Treats complications arising from various solid tumors.
• Works at an ESMO-accredited center that handles 6,000 patients annually.

Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).

He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.

Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Dr. Zamboglou leads the prostate cancer research group at University of Freiburg – a top German center for radiation oncology.

• Board-certified in radiotherapy and radiation oncology
• Expert panel member for German Society of Radiation Oncology
• Recipient of Herman-Holthusen Award for prostate cancer research
• Vice Medical Director at German Medical Institute in Cyprus
• Published researcher with multiple international awards

Dr. Sinan Karaaslan is an expert oncologist specializing in urogenital system cancers, including prostate cancer, at Anadolu Medical Center.

• 29 years of experience of experience in medical oncology
• Specialized training at Istanbul University's Cerrahpaşa Medical School
• Member of the Turkish Medical Oncology Society
• Focuses on immunotherapy and targeted therapies

Specializes in immunotherapy for prostate cancer with training at Hacettepe University Cancer Institute and MD Anderson Cancer Center.

• Experienced in treating various cancers including prostate, breast, and lung
• Completed fellowship at prestigious Hacettepe University Cancer Institute
• Trained at The University of Texas MD Anderson Cancer Center
• Works at Hisar Hospital Intercontinental

Professor Yesim Yildirim specializes in immunotherapy for prostate cancer at Anadolu Medical Center, with over 22 years of experience of focused oncology practice.

• Member of the European Society of Medical Oncology (ESMO)
• Author of 80+ international publications, including co-authoring cancer care handbooks
• Trained at Mount Vernon Cancer Center for melanoma and kidney cancer immunotherapy
• Professor at Haliç University, combining academic research with clinical practice

Assoc. Prof. Dr. Heves Sürmeli is a specialist in Internal Medicine and Medical Oncology. She received her medical degree (M.D.) from Eskişehir Osmangazi University in 2004. She completed her Internal Medicine residency at Kartal Dr. Lütfi Kırdar Training and Research Hospital, Istanbul (2005–2010). She then completed subspecialty training in Medical Oncology at the same hospital (2014–2017).

At the same center, she served as a Medical Oncology Specialist (2017–2023). She then worked as Administrative and Clinical Director (2023–2026). Her clinical interests include breast, lung, gynecologic, gastrointestinal, and urologic cancers.

She has published many articles in international peer‑reviewed journals. She has presented at national and international conferences. She is active in professional societies. She has received several awards.

Dr. Seref Komurcu is a medical oncologist at Anadolu Medical Center in Istanbul. He specializes in treating breast, lung, colorectal, and solid cancers. Dr. Komurcu holds both ECFMG and ESMO certifications. He previously served as a professor at Gülhane Military Medical Academy.

• Published over 110 scientific papers on cancer management.
• Provides immunotherapy, targeted therapy, and chemotherapy treatments.
• Member of the American Society of Clinical Oncology.
• Works at a clinic affiliated with Johns Hopkins Medicine.

Dr. Eda Tanrikulu is a clinical oncologist at Anadolu Medical Center in Istanbul. She ranked 3rd nationally in Turkey's minor specialty medical exam. Dr. Tanrikulu specializes in chemotherapy and individualized cancer treatments. She works at a facility affiliated with the Johns Hopkins Hospital.

• Served as the head of the medical oncology unit at Haydarpaşa Numune Hospital.
• Participated in global training at Oxford University and ESMO in Manchester.
• Treats gastrointestinal, urological, lung, and breast cancers.
• Member of the American and European Societies of Medical Oncology.

Dr. Necdet Uskent is a medical oncologist and hematologist at Anadolu Medical Center in Istanbul. He was part of the pioneering team that performed Turkey's first bone marrow transplant. Dr. Uskent holds the European Medical Oncology Certificate and focuses on breast, lung, and gastrointestinal cancers. He works at a facility affiliated with Johns Hopkins Medicine.

• Founder of the Turkish Oncology Group (TOG).
• A founding member of the Turkish Society of Medical Oncology.
• Served as a visiting lecturer at Royal Free and University College Hospital in London.
• Treats complex hematological conditions including lymphomas and myeloma.

Prof. Köstler is a leading expert in targeted cancer therapies, with over 22 years of experience of experience in medical oncology at Wiener Privatklinik.

• Specializes in breast cancer and gynecologic malignancies
• Associate Professor at the Medical University of Vienna
• Deputy Head of the Clinical Division of Oncology
• Focuses on biomarker development and tumor biology

Phd Viola Fox specializes in immunotherapy for prostate cancer, combining molecular diagnostics with personalized treatment plans at Medical Center in Solingen.

• 14 years of experience of experience in oncology and immunotherapy
• Chief Physician at a certified interdisciplinary cancer center
• Expert in molecular biology research for cancer treatments
• Member of American Association for Cancer Research
• Qualified specialist in genetics

Associate Professor Tahsin Ozatli specializes in treating breast, lung, and gastrointestinal cancers at Istinye Liv University Hospital.

• Board-certified oncologist with years of experience
• Previously worked at Ankara Oncology Clinic
• Promoted to Associate Professor in 2016
• Trained at Selcuk University Faculty of Medicine